164 related articles for article (PubMed ID: 29671355)
1. HDAC inhibitors: a 2013-2017 patent survey.
Faria Freitas M; Cuendet M; Bertrand P
Expert Opin Ther Pat; 2018 Apr; ():1-17. PubMed ID: 29671355
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
Zhao C; Dong H; Xu Q; Zhang Y
Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
[No Abstract] [Full Text] [Related]
3. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Simões-Pires CA; Bertrand P; Cuendet M
Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
[TBL] [Abstract][Full Text] [Related]
4. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
5. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
6. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Qin HT; Li HQ; Liu F
Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
[TBL] [Abstract][Full Text] [Related]
7. Exploration of the binding pocket of histone deacetylases: the design of potent and isoform-selective inhibitors.
Uba Aİ; Yelekçi K
Turk J Biol; 2017; 41(6):901-918. PubMed ID: 30814855
[TBL] [Abstract][Full Text] [Related]
8. Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016).
Zhan P; Wang X; Liu X; Suzuki T
Recent Pat Anticancer Drug Discov; 2017; 12(1):16-34. PubMed ID: 27804867
[TBL] [Abstract][Full Text] [Related]
9. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives.
Su M; Gong X; Liu F
Expert Opin Drug Discov; 2021 Jul; 16(7):745-761. PubMed ID: 33530771
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.
Kim JH; Ali KH; Oh YJ; Seo YH
Medicine (Baltimore); 2022 Apr; 101(17):e29049. PubMed ID: 35512065
[TBL] [Abstract][Full Text] [Related]
11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
12. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
13. An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 - present).
Liu YM; Liou JP
Expert Opin Ther Pat; 2023; 33(5):349-369. PubMed ID: 37249104
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).
Valente S; Mai A
Expert Opin Ther Pat; 2014 Apr; 24(4):401-15. PubMed ID: 24397271
[TBL] [Abstract][Full Text] [Related]
15. Explorative study on isoform-selective histone deacetylase inhibitors.
Suzuki T
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs).
Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S
Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894
[TBL] [Abstract][Full Text] [Related]
17. Inside HDACs with more selective HDAC inhibitors.
Roche J; Bertrand P
Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
[TBL] [Abstract][Full Text] [Related]
18. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
20. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]